A5051692712- CAR-T cell therapy research
- Virus-based gene therapy research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Pharmaceutical studies and practices
- Antifungal resistance and susceptibility
- Parvovirus B19 Infection Studies
- Central European Literary Studies
- Cytokine Signaling Pathways and Interactions
- Cystic Fibrosis Research Advances
- Cytomegalovirus and herpesvirus research
- Autoimmune and Inflammatory Disorders Research
- Childhood Cancer Survivors' Quality of Life
- Chronic Lymphocytic Leukemia Research
- Ecology and Vegetation Dynamics Studies
- Immunodeficiency and Autoimmune Disorders
- Language and Culture
- Forest ecology and management
- Bone Metabolism and Diseases
- Herpesvirus Infections and Treatments
- Fungal Infections and Studies
- Linguistic Education and Pedagogy
- Nanowire Synthesis and Applications
- Blood disorders and treatments
- Botany and Plant Ecology Studies
Wroclaw Medical University
2021-2025
Jagiellonian University
2010
Posaconazole is recommended for prophylaxis in pediatric immunocompromised patients. Due to its variability bioavailability and drug-to-drug interactions, EBMT recommends regimens based on therapeutic drug monitoring (TDM). In total, 171 oncohematological patients posaconazole were included. Full pharmacokinetic profiles assessed 51 children. The efficacy safety of was evaluated by measuring the concentration, with dose modification attempted suboptimal results. influence modifying factors...
CD19-targeted CAR-T cell therapy has revolutionized the treatment of relapsed/refractory (r/r) pre-B acute lymphoblastic leukemia (ALL). However, it can be associated with toxicities related to immune activation, particularly cytokine release syndrome (CRS) and effector cell-associated neurotoxicity (ICANS). Cytokines released from activated cells play a key role in their pathophysiology. This study was prospective analysis proinflammatory proteins cytokines children treated...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a lifesaving procedure in malignant and nonmalignant diseases. However, it associated with considerable risk of graft-versus-host disease (GvHD). Steroids are first-line therapy for acute GvHD (aGvHD), but there no standard treatment steroid-resistant (SR) gastrointestinal (GI) aGvHD, which has poor prognosis. The anti-integrin antibody, vedolizumab, could help controlling SR GI aGvHD symptoms by blocking lymphocyte...
Hematopoietic stem cell transplantation (HSCT) is a curative therapy for an increasing number of nonmalignant indications. Its use restricted by severe transplant-related complications, including CMV infection; despite various prophylactic and therapeutic strategies, reactivation has remarkable morbidity mortality. The analysis included 94 children with disorder who underwent allogeneic HSCT in the Department Pediatric Hematology, Oncology, Bone Marrow Transplantation Wrocław during years...
Introduction: Posaconazole, a second-generation triazole agent, is drug with wide interindividual variation in bioavailability and variability of pharmacokinetics. The European Conference on Infections Leukemia recommends the implementation posaconazole therapeutic monitoring (TDM) children to provide certainty regarding efficacy treatment increase its safety. A concentration plasma prophylactic regimens above 0.7 mg/L recommended. aim our pilot study was discover most effective method...
The optimal bridging therapy before CAR-T cell infusion in pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL) still remains an open question. administration of blinatumomab prior to is controversial since a potential loss CD19+ target cells may negatively impact the activation, persistence, and, as consequence, efficacy subsequently used cells. Here, we report single-center experience seven children with chemorefractory BCP-ALL treated either reduce...
When all of the usually applied treatment methods fail, we have to try something innovative. In this vignette, present history first in Poland CAR-T cell therapy a child with refractory B-cell acute lymphoblastic leukemia (ALL). more than 10 months observation time post infusion patient remains MRD-free chance for long awaited clinical cure.